Back to Journals » Risk Management and Healthcare Policy » Volume 5

Cost-effectiveness of screening for hepatocellular carcinoma: putting the cart before the horse

Authors Braillon A

Received 27 June 2012

Accepted for publication 28 June 2012

Published 9 August 2012 Volume 2012:5 Pages 91—92


Checked for plagiarism Yes

Alain Braillon

GRES, Public Health, Amiens, France

Ruggeri has recently reviewed the cost-effectiveness of screening for hepatocellular carcinoma (HCC).1 However, evidence for effectiveness is still lacking, with only two randomized trials available, both from China, one of which is negative and the other positive but with several major flaws.2 Only observational studies are available from developed countries, and conclude that screening improves survival, despite raw data showing that screened patients die younger than nonscreened patients, (length time and lead time biases).3 The National Cancer Institute recommends that “based on fair evidence, screening would not result in a decrease in mortality from HCC … based on fair evidence, screening would result in rare but serious side effects”.4

View original paper by Ruggeri.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.